Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study

BACKGROUND: Treatment with dupilumab, an anti-interleukin (IL)-4 receptor α monoclonal antibody that blocks both the IL-4 and IL-13 pathways, has demonstrated efficacy for the treatment of severe asthma (SA) with type 2 inflammation. However, few studies have focused on the efficacy of this biologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Numata, Takanori, Araya, Jun, Miyagawa, Hanae, Okuda, Keitaro, Takekoshi, Daisuke, Hashimoto, Mitsuo, Minagawa, Shunsuke, Ishikawa, Takeo, Hara, Hiromichi, Kuwano, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982811/
https://www.ncbi.nlm.nih.gov/pubmed/35392537
http://dx.doi.org/10.2147/JAA.S357548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982811/
https://www.ncbi.nlm.nih.gov/pubmed/35392537
http://dx.doi.org/10.2147/JAA.S357548

Ejemplares similares